Head to Head Survey: Helix Biopharma (OTCMKTS:HBPCF) & Synlogic (NASDAQ:SYBX)

Helix Biopharma (OTCMKTS:HBPCF) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Institutional and Insider Ownership

63.4% of Synlogic shares are held by institutional investors. 7.6% of Helix Biopharma shares are held by company insiders. Comparatively, 2.6% of Synlogic shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Helix Biopharma and Synlogic, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Helix Biopharma	0	0	0	0	0.00
Synlogic	1	0	0	0	1.00

Profitability

This table compares Helix Biopharma and Synlogic’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Helix Biopharma	N/A	-36.57%	-29.09%
Synlogic	N/A	-26.47%	-18.00%

Valuation & Earnings

This table compares Helix Biopharma and Synlogic”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Helix Biopharma	N/A	N/A	-$3.73 million	($0.05)	-34.20
Synlogic	$8,000.00	965.17	-$23.36 million	($0.06)	-11.00

Helix Biopharma has higher earnings, but lower revenue than Synlogic. Helix Biopharma is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Helix Biopharma has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500. Comparatively, Synlogic has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500.

Summary

Synlogic beats Helix Biopharma on 7 of the 10 factors compared between the two stocks.

About Helix Biopharma

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.

About Synlogic

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.